Candriam SCA’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Candriam SCA’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-240,000	Closed	-$928K	–	904
2023 Q1	$928K	Buy	240,000 +150,000	+167%	+$779K	0.01%	710
2022 Q4	$541K	Buy	+90,000	New	+$491K	﹤0.01%	800
2016 Q1	–	Sell	-151,500	Closed	-$1.86M	–	676
2015 Q4	$1.86M	Hold	151,500	–	–	0.05%	307
2015 Q3	$2.21M	Buy	151,500 +7,000	+5%	+$121K	0.05%	323
2015 Q2	$2.82M	Hold	144,500	–	–	0.06%	324
2015 Q1	$2.62M	Buy	144,500 +32,000	+28%	+$720K	0.05%	353
2014 Q4	$2.65M	Buy	+112,500	New	+$2.6M	0.06%	322

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Candriam SCA's CTIC Position: Q2 2023 in Review

Candriam SCA sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 240,000 shares — an estimated $928K sold.

Candriam SCA first reported a position in CTIC in Q4 2014 and held it in 7 quarters. The position peaked at $2.82M in Q2 2015. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Candriam SCA reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 240,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $928K.
Candriam SCA first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 7 quarters.
Candriam SCA's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.82M in Q2 2015.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.